Benjamin Edwards Inc. Has $1.19 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Benjamin Edwards Inc. grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 13,762.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 57,669 shares of the company's stock after purchasing an additional 57,253 shares during the period. Benjamin Edwards Inc. owned about 0.06% of Intellia Therapeutics worth $1,185,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its stake in shares of Intellia Therapeutics by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock valued at $29,648,000 after purchasing an additional 98,865 shares during the last quarter. Verition Fund Management LLC boosted its stake in shares of Intellia Therapeutics by 116.3% during the 3rd quarter. Verition Fund Management LLC now owns 94,426 shares of the company's stock worth $1,940,000 after acquiring an additional 50,763 shares in the last quarter. Thrivent Financial for Lutherans bought a new stake in shares of Intellia Therapeutics during the 2nd quarter worth about $679,000. American Century Companies Inc. increased its holdings in shares of Intellia Therapeutics by 23.8% during the 2nd quarter. American Century Companies Inc. now owns 330,514 shares of the company's stock valued at $7,397,000 after acquiring an additional 63,550 shares during the last quarter. Finally, Comerica Bank raised its stake in shares of Intellia Therapeutics by 853.6% in the 1st quarter. Comerica Bank now owns 37,105 shares of the company's stock valued at $1,021,000 after acquiring an additional 33,214 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NTLA has been the topic of several analyst reports. Canaccord Genuity Group reiterated a "buy" rating and set a $90.00 price target on shares of Intellia Therapeutics in a report on Tuesday, November 19th. Chardan Capital raised their target price on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a "buy" rating in a research note on Monday, November 18th. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a report on Friday, November 8th. JPMorgan Chase & Co. decreased their price target on shares of Intellia Therapeutics from $61.00 to $55.00 and set an "overweight" rating for the company in a report on Monday, August 12th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $54.94.

Intellia Therapeutics Trading Up 7.8 %

NTLA stock traded up $1.07 during midday trading on Friday, hitting $14.72. The stock had a trading volume of 2,821,292 shares, compared to its average volume of 2,724,545. Intellia Therapeutics, Inc. has a 52 week low of $12.82 and a 52 week high of $34.87. The stock has a 50-day simple moving average of $16.61 and a 200 day simple moving average of $20.98. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -2.71 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics's revenue was down 24.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.38) earnings per share. On average, equities analysts forecast that Intellia Therapeutics, Inc. will post -5.12 EPS for the current year.

Insiders Place Their Bets

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the transaction, the chief accounting officer now directly owns 47,012 shares of the company's stock, valued at approximately $893,698.12. This trade represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.20% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.